TTrialPathMatch Me to Trials
← Back to trials
RecruitingAdvanced Solid Tumor

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.

Sponsor: Fate Therapeutics

You may qualify if…

  • ✓ Histopathological or cytologically confirmed locally advanced or metastatic cancer that meets protocol-defined criteria
  • ✓ Disease that is not amenable to curative therapy, with prior therapies defined by specific tumor types
  • ✓ Contraceptive use by women and men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • ✓ Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • ✓ Presence of measurable disease by RECIST, v1.1 assessed within 28 days prior to start of first study intervention
  • ✓ Anticipated life expectancy of at least 3 months

You may not qualify if…

  • ✕ Females who are pregnant or breastfeeding
  • ✕ Evidence of inadequate organ function
  • ✕ Clinically significant cardiovascular disease
  • ✕ Known active central nervous system (CNS) involvement by malignancy
  • ✕ Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions within 2 years prior to study enrollment
  • ✕ Active bacterial, fungal, or viral infections
  • ✕ Prior receipt of chimeric antigen receptor (CAR) T-cell therapy, other cellular therapy, or a FATE investigational human induced pluripotent stem cell (iPSC) product
  • ✕ History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out based on imaging at screening

Where it's recruiting

Arizona

Gilbert

California

La Jolla

Connecticut

New Haven

Illinois

Chicago

Michigan

Detroit

Minnesota

Minneapolis

Missouri

St Louis

New York

New York

Ohio

Cincinnati · Columbus

Oklahoma

Oklahoma City

Pennsylvania

Philadelphia

Tennessee

Nashville

Source: ClinicalTrials.gov · NCT06241456 · last updated 2025-12-09

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclon · TrialPath